Cantor Fitzgerald Reiterates Overweight on AbbVie, Maintains $200 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on AbbVie (NYSE:ABBV) and maintains a $200 price target.
June 20, 2024 | 4:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on AbbVie and maintains a $200 price target.
The reiteration of an Overweight rating and a maintained price target of $200 by a reputable analyst can boost investor confidence in AbbVie, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100